- Trials with a EudraCT protocol (54)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
54 result(s) found for: Early warning score.
Displaying page 1 of 3.
| EudraCT Number: 2020-001597-30 | Sponsor Protocol Number: MRx-4DP0004-II-001 | Start Date*: 2020-05-29 | |||||||||||
| Sponsor Name:4D pharma plc | |||||||||||||
| Full Title: A pilot, multiple dose study to evaluate the efficacy and safety of MRx-4DP0004 in hospitalised patients with symptoms of COVID-19 (SARS-CoV-2 infection) | |||||||||||||
| Medical condition: Symptoms of Covid-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001511-25 | Sponsor Protocol Number: IMIB-COLVID-2020-03 | Start Date*: 2020-04-14 |
| Sponsor Name:FFIS | ||
| Full Title: Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 | ||
| Medical condition: COVID19 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001747-21 | Sponsor Protocol Number: ISPUP2020CT1 | Start Date*: 2020-07-06 | |||||||||||
| Sponsor Name:Instituto de Saúde Pública Universidade Porto | |||||||||||||
| Full Title: Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial | |||||||||||||
| Medical condition: Novel coronavirus pneumonia (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: PT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003367-26 | Sponsor Protocol Number: MK4482-001 | Start Date*: 2020-11-18 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19 | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) SE (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-018660-16 | Sponsor Protocol Number: SAP version1 01/01/2010 | Start Date*: 2010-04-22 |
| Sponsor Name:University Hospitals of leicester NHS Trust | ||
| Full Title: Randomised controlled trial on the effects of parenteral fish oil emulsion in patients with severe acute pancreatitis | ||
| Medical condition: Acute Pancreatitis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-001449-38 | Sponsor Protocol Number: CW002 | Start Date*: 2020-04-29 | |||||||||||
| Sponsor Name:Chelsea and Westminster Hospital NHS Foundation Trust | |||||||||||||
| Full Title: A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe | |||||||||||||
| Medical condition: COVID-19 Infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003872-42 | Sponsor Protocol Number: ANTIICIPATE | Start Date*: 2020-11-06 | ||||||||||||||||
| Sponsor Name:Istituto di Farmacologia Traslazionale - CNR | ||||||||||||||||||
| Full Title: Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patients | ||||||||||||||||||
| Medical condition: SARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 days | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-001770-30 | Sponsor Protocol Number: 2020COVID-19TCZ | Start Date*: 2020-04-21 | |||||||||||
| Sponsor Name:CHU AMBROISE PARE | |||||||||||||
| Full Title: COVID 19: Experimental use of tocilizumab (Roactemra®) in severe SARS-CoV-2 related pneumonia. | |||||||||||||
| Medical condition: viral pneumonia caused by the new coronavirus (SARS-CoV-2) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002728-35 | Sponsor Protocol Number: HUN-AVI-01 | Start Date*: 2020-09-17 | |||||||||||
| Sponsor Name:Hungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium | |||||||||||||
| Full Title: An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild Pneumonia − An open-label randomized controlled study − | |||||||||||||
| Medical condition: Patients with new type of coronavirus (SARS-CoV-2) infection proven by RT-PCR test with mild pneumonia. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001840-83 | Sponsor Protocol Number: SAGA | Start Date*: 2022-04-26 |
| Sponsor Name:University Medical Center Utrecht | ||
| Full Title: Short-course aminoglycosides as adjunctive treatment in adults with sepsis | ||
| Medical condition: Patients admitted with sepsis of unknown origin, suspected urinary origin or suspected abdominal origin | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003590-33 | Sponsor Protocol Number: 6.0-20-11-2019 | Start Date*: 2017-11-24 | |||||||||||||||||||||
| Sponsor Name:Bispebjerg University Hospital | |||||||||||||||||||||||
| Full Title: Pharmacokinetics of prednisolone in children with airway disease -The POP child | |||||||||||||||||||||||
| Medical condition: Asthma, pharmacokinetics | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-002120-37 | Sponsor Protocol Number: RESP301-002 | Start Date*: 2020-06-16 | |||||||||||
| Sponsor Name:Thirty Respiratory Limited | |||||||||||||
| Full Title: An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with C... | |||||||||||||
| Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001442-19 | Sponsor Protocol Number: IIBSP-COV-2020-23 | Start Date*: 2020-04-02 |
| Sponsor Name:INSTITUT DE RECERCA H. SANTA CREU I SANT PAU | ||
| Full Title: Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) | ||
| Medical condition: COVID19 | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002476-13 | Sponsor Protocol Number: 20HH5958 | Start Date*: 2020-07-24 | ||||||||||||||||||||||||||
| Sponsor Name:Imperial College London | ||||||||||||||||||||||||||||
| Full Title: A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. | ||||||||||||||||||||||||||||
| Medical condition: Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-001659-42 | Sponsor Protocol Number: ANTITROMBINA | Start Date*: 2020-04-18 | ||||||||||||||||
| Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
| Full Title: Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
| Medical condition: Confirmed SARS-CoV-2 respiratory infection with poor prognostic factors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-001512-26 | Sponsor Protocol Number: COMIHY | Start Date*: 2020-04-22 | |||||||||||
| Sponsor Name:Universitätsklinikum Tübingen | |||||||||||||
| Full Title: Hydroxychloroquine for the treatment of mild COVID-19 disease | |||||||||||||
| Medical condition: Acute coronavirus disease 2019 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001203-16 | Sponsor Protocol Number: LIBERATE | Start Date*: 2020-05-06 | |||||||||||||||||||||
| Sponsor Name:Guy's and St Thomas' NHS Foundation Trust [...] | |||||||||||||||||||||||
| Full Title: Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial | |||||||||||||||||||||||
| Medical condition: COVID-19; respiratory failure; hypoxaemia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2020-003107-34 | Sponsor Protocol Number: SHAPERON001 | Start Date*: 2020-08-19 |
| Sponsor Name:Shaperon Inc | ||
| Full Title: A randomized, double blind, placebo-controlled, phase 2 clinical trial to investigate the efficacy and safety of 2 doses of NuSepin® intravenous infusion in Covid-19 pneumonia patients | ||
| Medical condition: Adult subjects with Covid-19 pneumonia | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: RO (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002753-22 | Sponsor Protocol Number: FAVID-01-20-SP | Start Date*: 2020-09-02 | |||||||||||
| Sponsor Name:Ferrer Internacional, S.A. | |||||||||||||
| Full Title: Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia −A randomized, double blind, placebo- controlled study − | |||||||||||||
| Medical condition: Patients diagnosed with COVID-19 by positive PCR for SARS-COV2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-001541-39 | Sponsor Protocol Number: BEVACOR | Start Date*: 2020-04-24 | ||||||||||||||||
| Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
| Full Title: Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
| Medical condition: Acute respiratory distress syndrome in patients with COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.